Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer that has come back or stopped responding to treatment), confirmed by a tissue sample test.
- People who received at least one dose of the medicines tafasitamab and lenalidomide together through a special access program in Italy (known as the NPP, under a specific regulation), between April 2022 and December 2022.
- People who were 18 years of age or older at the time of enrollment.
- People who have signed a written consent form agreeing to take part (where this is required).
Who may not be able to join:
- People with relapsed or refractory diffuse large B-cell lymphoma who received tafasitamab together with lenalidomide as part of a different clinical trial (rather than through the special access program mentioned above).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pier Luigi Zinzani, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Phone: +39 0512144042
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
overall response rate (ORR)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.